Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb and Exelixis reported phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.
The study evaluates the safety, tolerability, and clinical activity of XL184 at continuous daily doses of 175 mg or 125 mg in patients with previously treated GBM, including some patients who had received prior antiangiogenic therapy.

Nov 12 · 4:49:00 PM · Source: Business Wire · Related: Exelixis Inc.
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto